dasatinib ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 785 302962-49-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dasatinib
  • sprycel
  • spyrcel
  • BMS-354825
  • dasatinib hydrate
A pyrimidine and thiazole derived ANTINEOPLASTIC AGENT and PROTEIN KINASE INHIBITOR of BCR-ABL KINASE. It is used in the treatment of patients with CHRONIC MYELOID LEUKEMIA who are resistant or intolerant to IMATINIB.
  • Molecular weight: 488.01
  • Formula: C22H26ClN7O2S
  • CLOGP: 2.71
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 3
  • TPSA: 106.51
  • ALOGS: -4.58
  • ROTB: 7

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.10 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 5.85 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 15 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Nov. 20, 2006 EMA BRISTOL-MYERS SQUIBB PHARMA EEIG
June 28, 2006 FDA BRISTOL MYERS SQUIBB

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pleural effusion 1290.86 18.17 608 17095 80846 50506575
Adverse event 297.14 18.17 187 17516 43576 50543845
Prescribed underdose 294.82 18.17 133 17570 15816 50571605
Drug resistance 275.68 18.17 134 17569 18855 50568566
Cytogenetic analysis abnormal 223.66 18.17 52 17651 694 50586727
Malignant neoplasm progression 220.76 18.17 186 17517 67938 50519483
Philadelphia chromosome positive 217.41 18.17 45 17658 334 50587087
Hospitalisation 198.81 18.17 175 17528 67762 50519659
Pulmonary oedema 173.86 18.17 141 17562 48797 50538624
Acute lymphocytic leukaemia recurrent 169.14 18.17 51 17652 1924 50585497
Exposure via body fluid 164.48 18.17 37 17666 422 50586999
Pericardial effusion 138.55 18.17 95 17608 25494 50561927
Blast crisis in myelogenous leukaemia 128.97 18.17 31 17672 481 50586940
Fluid retention 118.08 18.17 115 17588 50534 50536887
Nausea 117.28 18.17 521 17182 704877 49882544
Chylothorax 109.74 18.17 24 17679 238 50587183
Diarrhoea 103.19 18.17 442 17261 588034 49999387
Rash 103.08 18.17 361 17342 437110 50150311
Death 92.17 18.17 286 17417 325093 50262328
Headache 77.70 18.17 366 17337 506169 50081252
Thrombocytopenia 76.70 18.17 150 17553 127523 50459898
Chronic myeloid leukaemia transformation 74.26 18.17 15 17688 97 50587324
Blast cell crisis 66.55 18.17 13 17690 69 50587352
Bone pain 62.82 18.17 80 17623 47149 50540272
Pancytopenia 60.81 18.17 107 17596 83923 50503498
Chronic myeloid leukaemia recurrent 59.32 18.17 14 17689 200 50587221
Fatigue 57.65 18.17 433 17270 707168 49880253
Large granular lymphocytosis 55.80 18.17 13 17690 175 50587246
Enterocolitis haemorrhagic 55.30 18.17 20 17683 1337 50586084
Bone marrow transplant 47.98 18.17 15 17688 639 50586782
Fall 47.90 18.17 29 17674 334903 50252518
Chronic myeloid leukaemia 46.32 18.17 20 17683 2136 50585285
Therapeutic response delayed 45.95 18.17 14 17689 547 50586874
Leukaemia recurrent 45.62 18.17 17 17686 1237 50586184
Pulmonary hypertension 45.05 18.17 57 17646 33360 50554061
Infusion related reaction 44.62 18.17 4 17699 169553 50417868
Haematotoxicity 44.34 18.17 30 17673 7865 50579556
Acne 42.85 18.17 43 17660 19552 50567869
Anaemia 41.88 18.17 187 17516 252269 50335152
Acute graft versus host disease 40.24 18.17 22 17681 3936 50583485
Product dose omission issue 39.87 18.17 148 17555 183690 50403731
Myalgia 39.49 18.17 114 17589 124205 50463216
Condition aggravated 39.36 18.17 28 17675 297030 50290391
Polymerase chain reaction positive 38.23 18.17 8 17695 63 50587358
Aspiration pleural cavity 37.75 18.17 13 17690 752 50586669
Platelet count decreased 37.59 18.17 98 17605 100628 50486793
Nephrotic syndrome 36.42 18.17 22 17681 4748 50582673
Joint swelling 35.37 18.17 21 17682 245265 50342156
Lymphoid tissue hyperplasia 35.15 18.17 9 17694 183 50587238
Enterococcal bacteraemia 34.88 18.17 14 17689 1244 50586177
Neutropenia 34.50 18.17 122 17581 147843 50439578
Therapeutic product effect decreased 33.74 18.17 4 17699 136046 50451375
Dyspnoea 33.16 18.17 314 17389 547294 50040127
Pulmonary arterial hypertension 32.84 18.17 38 17665 20281 50567140
Cytopenia 32.63 18.17 26 17677 8749 50578672
Drug hypersensitivity 30.27 18.17 26 17677 250984 50336437
Therapy cessation 28.35 18.17 40 17663 25971 50561450
Arthropathy 28.21 18.17 10 17693 157896 50429525
Stem cell transplant 27.94 18.17 13 17690 1655 50585766
Hepatitis chronic active 27.66 18.17 6 17697 57 50587364
Normal newborn 27.43 18.17 21 17682 6670 50580751
Systemic candida 26.97 18.17 15 17688 2775 50584646
Graft versus host disease 26.71 18.17 20 17683 6146 50581275
Chronic graft versus host disease 26.59 18.17 15 17688 2852 50584569
Alopecia 26.36 18.17 161 17542 244886 50342535
Pleurisy 25.73 18.17 21 17682 7310 50580111
Acquired gene mutation 25.67 18.17 10 17693 821 50586600
Gene mutation identification test positive 23.62 18.17 6 17697 118 50587303
Cytomegalovirus colitis 23.23 18.17 12 17691 1915 50585506
Cytomegalovirus enterocolitis 21.75 18.17 8 17695 561 50586860
Lymphocytosis 21.72 18.17 12 17691 2190 50585231
Gene mutation 21.58 18.17 10 17693 1261 50586160
Febrile neutropenia 21.44 18.17 79 17624 97588 50489833
Demyelinating polyneuropathy 21.26 18.17 8 17695 598 50586823
Hypotension 21.15 18.17 31 17672 235438 50351983
Subdural haematoma 20.56 18.17 24 17679 12923 50574498
Intentional product use issue 20.17 18.17 66 17637 76852 50510569
Full blood count decreased 19.54 18.17 31 17672 22315 50565106
Discomfort 19.12 18.17 7 17696 108373 50479048
Leukaemia 18.94 18.17 13 17690 3486 50583935
Central nervous system leukaemia 18.90 18.17 5 17698 116 50587305
Blast cell proliferation 18.80 18.17 3 17700 3 50587418
Philadelphia positive chronic myeloid leukaemia 18.54 18.17 4 17699 37 50587384
Product storage error 18.32 18.17 22 17681 12202 50575219

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pleural effusion 1673.83 17.11 821 16578 71087 29486041
Drug resistance 413.26 17.11 217 17182 21323 29535805
Adverse event 378.20 17.11 183 17216 15108 29542020
Philadelphia chromosome positive 332.80 17.11 68 17331 252 29556876
Prescribed underdose 267.07 17.11 117 17282 7669 29549459
Malignant neoplasm progression 237.44 17.11 253 17146 73606 29483522
Cytogenetic analysis abnormal 215.75 17.11 53 17346 517 29556611
Hospitalisation 208.16 17.11 190 17209 45798 29511330
Blast crisis in myelogenous leukaemia 172.61 17.11 44 17355 505 29556623
Drug intolerance 161.08 17.11 169 17230 48210 29508918
Chylothorax 160.31 17.11 43 17356 610 29556518
Pericardial effusion 129.25 17.11 104 17295 21104 29536024
Fluid retention 125.80 17.11 107 17292 23453 29533675
Headache 118.54 17.11 293 17106 173714 29383414
Pulmonary oedema 109.05 17.11 130 17269 42605 29514523
Acute lymphocytic leukaemia recurrent 100.04 17.11 42 17357 2474 29554654
Gene mutation 91.29 17.11 31 17368 1010 29556118
Fatigue 83.30 17.11 387 17012 316434 29240694
Large granular lymphocytosis 83.04 17.11 20 17379 178 29556950
Pulmonary hypertension 72.79 17.11 71 17328 18537 29538591
Death 69.64 17.11 389 17010 341695 29215433
Acquired gene mutation 67.29 17.11 26 17373 1232 29555896
Rash 65.34 17.11 252 17147 189567 29367561
Loss of therapeutic response 59.44 17.11 17 17382 309 29556819
Acne 57.81 17.11 46 17353 9174 29547954
Diarrhoea 56.51 17.11 361 17038 332337 29224791
Chronic myeloid leukaemia transformation 51.66 17.11 13 17386 141 29556987
Thrombocytopenia 47.12 17.11 180 17219 134643 29422485
Blast cell proliferation 47.04 17.11 8 17391 6 29557122
Chronic myeloid leukaemia 46.63 17.11 23 17376 1971 29555157
Aspiration pleural cavity 45.09 17.11 17 17382 753 29556375
Pulmonary arterial hypertension 44.23 17.11 36 17363 7413 29549715
Bone pain 41.94 17.11 53 17346 18399 29538729
Hypotension 41.79 17.11 32 17367 194322 29362806
Chronic myeloid leukaemia recurrent 40.37 17.11 11 17388 166 29556962
Lymphoid tissue hyperplasia 39.40 17.11 9 17390 62 29557066
Bone marrow transplant 38.40 17.11 16 17383 924 29556204
Central nervous system neoplasm 37.89 17.11 9 17390 75 29557053
Intentional product use issue 35.83 17.11 78 17321 42420 29514708
Gene mutation identification test positive 33.99 17.11 9 17390 121 29557007
Loss of CAR T-cell persistence 33.82 17.11 7 17392 28 29557100
Therapy cessation 33.60 17.11 42 17357 14420 29542708
Natural killer cell count increased 32.20 17.11 5 17394 0 29557128
Therapy change 30.42 17.11 19 17380 2579 29554549
Enterocolitis haemorrhagic 29.86 17.11 13 17386 837 29556291
Oedema 29.35 17.11 70 17329 40413 29516715
Drug clearance decreased 29.06 17.11 15 17384 1415 29555713
Condition aggravated 29.05 17.11 26 17373 146269 29410859
Leukaemia recurrent 28.60 17.11 15 17384 1462 29555666
Pleurisy 28.28 17.11 22 17377 4245 29552883
Bone marrow disorder 27.90 17.11 15 17384 1537 29555591
Philadelphia positive chronic myeloid leukaemia 26.94 17.11 7 17392 87 29557041
Platelet count decreased 26.63 17.11 127 17272 104545 29452583
Product dose omission issue 26.03 17.11 119 17280 96264 29460864
Bradycardia 25.58 17.11 4 17395 65625 29491503
Anterior interosseous syndrome 25.27 17.11 5 17394 15 29557113
Hyperplasia 24.87 17.11 10 17389 527 29556601
Clonal evolution 24.59 17.11 7 17392 125 29557003
Neoplasm recurrence 24.52 17.11 15 17384 1962 29555166
Chromosome analysis abnormal 24.08 17.11 7 17392 135 29556993
Toxicity to various agents 23.84 17.11 41 17358 173620 29383508
Fall 22.39 17.11 44 17355 177134 29379994
Hyphaema 22.30 17.11 9 17390 479 29556649
Blast cell crisis 21.99 17.11 6 17393 91 29557037
Peripheral arterial occlusive disease 21.03 17.11 20 17379 5056 29552072
Graft versus host disease 20.84 17.11 27 17372 9601 29547527
B-cell small lymphocytic lymphoma 20.49 17.11 6 17393 119 29557009
Gelatinous transformation of the bone marrow 20.48 17.11 4 17395 11 29557117
Cytopenia 20.34 17.11 27 17372 9832 29547296
Nausea 20.19 17.11 259 17140 288996 29268132
Central nervous system leukaemia 19.79 17.11 7 17392 258 29556870
Second primary malignancy 19.77 17.11 22 17377 6683 29550445
Treatment failure 19.73 17.11 57 17342 36882 29520246
Bone neoplasm 19.54 17.11 7 17392 268 29556860
Hyperkalaemia 19.37 17.11 6 17393 61386 29495742
Rectosigmoid cancer 19.14 17.11 6 17393 151 29556977
Loss of consciousness 18.88 17.11 10 17389 74046 29483082
Hepatotoxicity 18.85 17.11 36 17363 17831 29539297
Myeloproliferative neoplasm 18.72 17.11 8 17391 492 29556636
Allogenic bone marrow transplantation therapy 18.13 17.11 4 17395 23 29557105
Peripheral artery stenosis 17.54 17.11 9 17390 838 29556290

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pleural effusion 2454.26 15.21 1131 24709 125428 64347464
Drug resistance 499.11 15.21 255 25585 34847 64438045
Philadelphia chromosome positive 423.52 15.21 87 25753 530 64472362
Malignant neoplasm progression 354.83 15.21 321 25519 112550 64360342
Chylothorax 304.93 15.21 66 25774 534 64472358
Prescribed underdose 288.64 15.21 142 25698 17873 64455019
Cytogenetic analysis abnormal 267.51 15.21 65 25775 916 64471976
Pericardial effusion 239.01 15.21 165 25675 39089 64433803
Blast crisis in myelogenous leukaemia 227.75 15.21 55 25785 754 64472138
Pulmonary oedema 186.95 15.21 192 25648 78482 64394410
Acute lymphocytic leukaemia recurrent 176.95 15.21 65 25775 3961 64468931
Hospitalisation 156.40 15.21 171 25669 75036 64397856
Fluid retention 153.53 15.21 152 25688 59454 64413438
Large granular lymphocytosis 147.47 15.21 33 25807 316 64472576
Adverse event 143.25 15.21 122 25718 39367 64433525
Rash 119.72 15.21 429 25411 458120 64014772
Death 117.13 15.21 441 25399 482264 63990628
Thrombocytopenia 115.73 15.21 268 25572 223533 64249359
Chronic myeloid leukaemia transformation 113.92 15.21 25 25815 217 64472675
Headache 97.14 15.21 444 25396 529023 63943869
Diarrhoea 96.39 15.21 554 25286 722150 63750742
Acquired gene mutation 94.49 15.21 34 25806 1952 64470940
Gene mutation 92.92 15.21 34 25806 2048 64470844
Enterocolitis haemorrhagic 90.84 15.21 33 25807 1947 64470945
Chronic myeloid leukaemia 80.26 15.21 35 25805 3339 64469553
Acne 73.02 15.21 66 25774 23015 64449877
Pulmonary arterial hypertension 71.48 15.21 68 25772 25299 64447593
Pulmonary hypertension 70.99 15.21 87 25753 43052 64429840
Fatigue 68.69 15.21 523 25317 748207 63724685
Aspiration pleural cavity 62.43 15.21 23 25817 1412 64471480
Therapy cessation 60.84 15.21 70 25770 32419 64440473
Fall 58.18 15.21 49 25791 416777 64056115
Pancytopenia 57.54 15.21 156 25684 143153 64329739
Platelet count decreased 57.08 15.21 172 25668 167539 64305353
Febrile neutropenia 57 15.21 185 25655 187472 64285420
Condition aggravated 54.19 15.21 42 25798 372384 64100508
Pleurisy 54.03 15.21 38 25802 9253 64463639
Bone marrow transplant 53.69 15.21 20 25820 1267 64471625
Blast cell crisis 51.78 15.21 12 25828 136 64472756
Bone pain 51.04 15.21 78 25762 47494 64425398
Blast cell proliferation 50.11 15.21 8 25832 6 64472886
Therapy change 48.69 15.21 31 25809 6403 64466489
Philadelphia positive chronic myeloid leukaemia 47.36 15.21 11 25829 126 64472766
Nausea 46.33 15.21 499 25341 785301 63687591
Infusion related reaction 45.58 15.21 6 25834 164461 64308431
Hypotension 44.83 15.21 52 25788 380922 64091970
Drug clearance decreased 42.98 15.21 21 25819 2598 64470294
Natural killer cell count increased 41.15 15.21 7 25833 11 64472881
Leukaemia recurrent 40.19 15.21 20 25820 2574 64470318
Chronic myeloid leukaemia recurrent 39.33 15.21 11 25829 275 64472617
Full blood count decreased 37.88 15.21 46 25794 22536 64450356
Therapeutic response delayed 37.87 15.21 14 25826 868 64472024
Cytomegalovirus colitis 37.61 15.21 22 25818 3906 64468986
Chromosome analysis abnormal 37.23 15.21 10 25830 214 64472678
Clonal evolution 37.05 15.21 10 25830 218 64472674
Graft versus host disease 36.97 15.21 36 25804 13777 64459115
Oedema 36.79 15.21 100 25740 91835 64381057
Anaemia 35.90 15.21 267 25573 378413 64094479
Enterococcal bacteraemia 34.97 15.21 18 25822 2487 64470405
Loss of therapeutic response 34.77 15.21 10 25830 277 64472615
Central nervous system neoplasm 34.42 15.21 8 25832 92 64472800
Neutropenia 33.85 15.21 187 25653 239437 64233455
Haematotoxicity 33.37 15.21 33 25807 12863 64460029
Toxicity to various agents 32.57 15.21 60 25780 363453 64109439
Therapeutic product effect decreased 32.46 15.21 4 25836 115347 64357545
Drug intolerance 32.31 15.21 155 25685 187837 64285055
Mucosal inflammation 32.30 15.21 75 25765 62509 64410383
Colitis 32.15 15.21 72 25768 58602 64414290
Drug hypersensitivity 31.87 15.21 29 25811 237786 64235106
Loss of CAR T-cell persistence 31.29 15.21 6 25834 24 64472868
Lymphoid tissue hyperplasia 31.14 15.21 9 25831 254 64472638
Somnolence 30.82 15.21 22 25818 203623 64269269
Joint swelling 30.39 15.21 25 25815 215357 64257535
Polymerase chain reaction positive 30.21 15.21 9 25831 283 64472609
Nephrotic syndrome 29.55 15.21 27 25813 9540 64463352
Pyrexia 27.96 15.21 344 25496 558300 63914592
Central nervous system leukaemia 27.75 15.21 9 25831 376 64472516
Bone marrow failure 27.58 15.21 60 25780 47892 64425000
Bone marrow disorder 27.52 15.21 16 25824 2809 64470083
Growth retardation 27.08 15.21 13 25827 1548 64471344
Minimal residual disease 27.05 15.21 9 25831 408 64472484
Systemic candida 26.89 15.21 20 25820 5309 64467583
Cytopenia 26.74 15.21 32 25808 15439 64457453
Lymphocytosis 26.20 15.21 17 25823 3627 64469265
Arthropathy 26.08 15.21 8 25832 120959 64351933
Cytomegalovirus enterocolitis 25.70 15.21 12 25828 1343 64471549
Anterior interosseous syndrome 25.51 15.21 5 25835 23 64472869
Multiple-drug resistance 25.44 15.21 21 25819 6481 64466411
Musculoskeletal stiffness 25.07 15.21 9 25831 123197 64349695
Lower respiratory tract infection 24.93 15.21 4 25836 94610 64378282
Hyperplasia 24.80 15.21 11 25829 1093 64471799
Stem cell transplant 24.44 15.21 16 25824 3465 64469427
Dyspnoea 24.22 15.21 413 25427 718261 63754631
Haemothorax 24.05 15.21 18 25822 4824 64468068
Peripheral artery stenosis 23.84 15.21 11 25829 1198 64471694
Transplant 23.83 15.21 10 25830 868 64472024
Gene mutation identification test positive 23.65 15.21 7 25833 215 64472677
Bradycardia 23.45 15.21 9 25831 118210 64354682
Intentional overdose 23.26 15.21 4 25836 89940 64382952
Skin toxicity 23.11 15.21 20 25820 6582 64466310
Hyphaema 23.08 15.21 9 25831 646 64472246
White blood cell count decreased 22.81 15.21 124 25716 157713 64315179
Therapy non-responder 22.77 15.21 68 25772 65831 64407061
Product administered to patient of inappropriate age 22.62 15.21 17 25823 4584 64468308
Syncope 22.60 15.21 18 25822 157617 64315275
Generalised oedema 22.09 15.21 34 25806 20819 64452073
Mobility decreased 21.80 15.21 4 25836 85836 64387056
Oxygen saturation decreased 21.52 15.21 8 25832 107168 64365724
Cytomegalovirus infection reactivation 21.30 15.21 18 25822 5738 64467154
Acute graft versus host disease 21.23 15.21 22 25818 9062 64463830
Loss of consciousness 21.20 15.21 17 25823 148348 64324544
Acute lymphocytic leukaemia 21.15 15.21 16 25824 4355 64468537
Overdose 20.72 15.21 20 25820 159546 64313346
Myalgia 20.54 15.21 121 25719 158496 64314396
Hydrothorax 20.39 15.21 10 25830 1247 64471645
Hepatitis chronic active 20.37 15.21 6 25834 181 64472711
Peripheral arterial occlusive disease 20.19 15.21 19 25821 6968 64465924
Therapeutic response decreased 20.10 15.21 56 25784 52132 64420760
Splenomegaly 20.04 15.21 30 25810 17931 64454961
Intentional product use issue 19.64 15.21 83 25757 95281 64377611
Periorbital oedema 19.24 15.21 19 25821 7395 64465497
Neoplasm malignant 19.13 15.21 35 25805 24653 64448239
Tremor 18.76 15.21 19 25821 148211 64324681
Metabolic acidosis 18.69 15.21 3 25837 70955 64401937
Hepatotoxicity 18.58 15.21 46 25794 39916 64432976
Subdural haematoma 18.34 15.21 37 25803 28017 64444875
Allogenic bone marrow transplantation therapy 18.30 15.21 4 25836 34 64472858
Tumour lysis syndrome 18.26 15.21 30 25810 19410 64453482
Bacteraemia 18.20 15.21 36 25804 26875 64446017
Chronic graft versus host disease 18.01 15.21 17 25823 6259 64466633
Bone development abnormal 17.45 15.21 4 25836 43 64472849
Blast cell count increased 17.31 15.21 9 25831 1270 64471622
Pneumonia 17.17 15.21 317 25523 559259 63913633
Leukaemia 16.98 15.21 15 25825 5073 64467819
Alopecia 16.90 15.21 119 25721 165571 64307321
Eye swelling 16.53 15.21 31 25809 22250 64450642
Glossodynia 16.46 15.21 3 25837 64693 64408199
Cytomegalovirus infection 16.43 15.21 42 25798 37157 64435735
Confusional state 16.32 15.21 52 25788 261092 64211800
Demyelinating polyneuropathy 16.10 15.21 9 25831 1467 64471425
C-reactive protein increased 16.07 15.21 9 25831 94900 64377992
Polyhydramnios 16.03 15.21 9 25831 1478 64471414
Second primary malignancy 15.80 15.21 22 25818 12315 64460577
Normal newborn 15.71 15.21 15 25825 5602 64467290
Balance disorder 15.65 15.21 7 25833 83919 64388973
White blood cell count increased 15.62 15.21 60 25780 65954 64406938
Hypersensitivity 15.38 15.21 35 25805 196417 64276475
Coma 15.29 15.21 8 25832 87607 64385285
Cardiac failure 15.25 15.21 98 25742 132275 64340617
Decreased appetite 15.24 15.21 176 25664 281113 64191779

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01EA02 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
BCR-ABL tyrosine kinase inhibitors
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D047428 Protein Kinase Inhibitors
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:38637 tyrosine kinase inhibitors
CHEBI has role CHEBI:149553 anticoronaviral drug

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Blastic phase chronic myeloid leukemia indication 413656006
Chronic phase chronic myeloid leukemia indication 413847001
Philadelphia chromosome-positive acute lymphoblastic leukemia indication 425688002
Philadelphia Chromosome Positive Chronic Myelocytic Leukemia indication
Chronic Myelocytic Leukemia Accelerated Phase indication
Acute hemorrhage contraindication 8573003
Myocardial infarction contraindication 22298006 DOID:5844
Torsades de pointes contraindication 31722008
Body fluid retention contraindication 43498006
Chronic heart failure contraindication 48447003
Gastrointestinal hemorrhage contraindication 74474003
Left heart failure contraindication 85232009
Prolonged QT interval contraindication 111975006
Disease of liver contraindication 235856003 DOID:409
Edema contraindication 267038008
Anemia contraindication 271737000 DOID:2355
Cerebral hemorrhage contraindication 274100004
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Pericardial effusion contraindication 373945007 DOID:118
Ascites contraindication 389026000
Breastfeeding (mother) contraindication 413712001
Congenital long QT syndrome contraindication 442917000
Pleural Effusions contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.56 acidic
pKa2 7.72 Basic
pKa3 4.89 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
100MG SPRYCEL BRISTOL MYERS SQUIBB N021986 May 30, 2008 RX TABLET ORAL June 21, 2022 PEDIATRIC EXCLUSIVITY
140MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL June 21, 2022 PEDIATRIC EXCLUSIVITY
20MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL June 21, 2022 PEDIATRIC EXCLUSIVITY
50MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL June 21, 2022 PEDIATRIC EXCLUSIVITY
70MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL June 21, 2022 PEDIATRIC EXCLUSIVITY
80MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL June 21, 2022 PEDIATRIC EXCLUSIVITY
100MG SPRYCEL BRISTOL MYERS SQUIBB N021986 May 30, 2008 RX TABLET ORAL Nov. 9, 2024 TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
140MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL Nov. 9, 2024 TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
20MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL Nov. 9, 2024 TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
50MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL Nov. 9, 2024 TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
70MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL Nov. 9, 2024 TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
80MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL Nov. 9, 2024 TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
100MG SPRYCEL BRISTOL MYERS SQUIBB N021986 May 30, 2008 RX TABLET ORAL May 9, 2025 PEDIATRIC EXCLUSIVITY
140MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL May 9, 2025 PEDIATRIC EXCLUSIVITY
20MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL May 9, 2025 PEDIATRIC EXCLUSIVITY
50MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL May 9, 2025 PEDIATRIC EXCLUSIVITY
70MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL May 9, 2025 PEDIATRIC EXCLUSIVITY
80MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL May 9, 2025 PEDIATRIC EXCLUSIVITY
100MG SPRYCEL BRISTOL MYERS SQUIBB N021986 May 30, 2008 RX TABLET ORAL Dec. 21, 2025 INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
140MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL Dec. 21, 2025 INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
20MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL Dec. 21, 2025 INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
50MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL Dec. 21, 2025 INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
70MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL Dec. 21, 2025 INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
80MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL Dec. 21, 2025 INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
100MG SPRYCEL BRISTOL MYERS SQUIBB N021986 May 30, 2008 RX TABLET ORAL June 21, 2026 PEDIATRIC EXCLUSIVITY
140MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL June 21, 2026 PEDIATRIC EXCLUSIVITY
20MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL June 21, 2026 PEDIATRIC EXCLUSIVITY
50MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL June 21, 2026 PEDIATRIC EXCLUSIVITY
70MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL June 21, 2026 PEDIATRIC EXCLUSIVITY
80MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL June 21, 2026 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Mast/stem cell growth factor receptor Kit Kinase INHIBITOR Kd 9.24 CHEMBL CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase INHIBITOR Kd 9.68 CHEMBL CHEMBL
Tyrosine-protein kinase Lck Kinase INHIBITOR Kd 9.70 CHEMBL CHEMBL
Tyrosine-protein kinase Yes Kinase INHIBITOR Kd 9.52 CHEMBL CHEMBL
Tyrosine-protein kinase Fyn Kinase INHIBITOR Kd 9.10 CHEMBL CHEMBL
Ephrin type-A receptor 2 Kinase INHIBITOR Kd 9.07 CHEMBL CHEMBL
Platelet-derived growth factor receptor beta Kinase INHIBITOR Kd 9.20 CHEMBL CHEMBL
Tyrosine-protein kinase ABL1 Kinase INHIBITOR IC50 9.60 IUPHAR CHEMBL
Vascular endothelial growth factor receptor 1 Kinase Kd 5.30 CHEMBL
Vascular endothelial growth factor receptor 2 Kinase Kd 5.54 CHEMBL
Macrophage colony-stimulating factor 1 receptor Kinase Kd 9.24 CHEMBL
Platelet-derived growth factor receptor alpha Kinase Kd 9.33 CHEMBL
Receptor tyrosine-protein kinase erbB-2 Kinase Kd 5.85 CHEMBL
Myosin light chain kinase, smooth muscle Kinase Kd 7.14 CHEMBL
Fibroblast growth factor receptor 3 Kinase Kd 5.41 CHEMBL
Tyrosine-protein kinase HCK Kinase INHIBITOR Kd 9.46 CHEMBL
Receptor tyrosine-protein kinase erbB-4 Kinase Kd 7.26 CHEMBL
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Kinase IC50 4.52 CHEMBL
cAMP-dependent protein kinase catalytic subunit beta Kinase Kd 5.92 CHEMBL
Tyrosine-protein kinase JAK2 Kinase Kd 6 CHEMBL
Tyrosine-protein kinase SYK Kinase Kd 5.54 CHEMBL
Myosin light chain kinase 2, skeletal/cardiac muscle Kinase Kd 5.46 CHEMBL
Tyrosine-protein kinase CSK Kinase Kd 9 CHEMBL
Ephrin type-A receptor 8 Kinase Kd 9.62 CHEMBL
Tyrosine-protein kinase Lyn Kinase INHIBITOR Kd 9.24 CHEMBL
Cytoplasmic tyrosine-protein kinase BMX Kinase Kd 8.85 CHEMBL
Serine/threonine-protein kinase Nek2 Kinase Kd 5.19 CHEMBL
LIM domain kinase 1 Kinase Kd 6.24 CHEMBL
Fibroblast growth factor receptor 1 Kinase Kd 5.43 CHEMBL
Serine/threonine-protein kinase 10 Kinase Kd 5.92 CHEMBL
Abelson tyrosine-protein kinase 2 Kinase Kd 9.77 CHEMBL
Mitogen-activated protein kinase 11 Kinase Kd 6.39 CHEMBL
Ephrin type-A receptor 5 Kinase Kd 9.62 CHEMBL
Ephrin type-A receptor 4 Kinase Kd 8.92 CHEMBL
Fibroblast growth factor receptor 2 Kinase Kd 5.85 CHEMBL
Serine/threonine-protein kinase N1 Kinase Kd 6.45 CHEMBL
Protein kinase C theta type Kinase Kd 6.15 CHEMBL
Ephrin type-A receptor 6 Kinase Kd 5.68 CHEMBL
TRAF2 and NCK-interacting protein kinase Kinase Kd 5.70 CHEMBL
Casein kinase I isoform epsilon Kinase Kd 5.82 CHEMBL
Tyrosine-protein kinase Fgr Kinase INHIBITOR Kd 9.30 CHEMBL
Aurora kinase A Kinase Kd 5.03 CHEMBL
Serine/threonine-protein kinase 36 Kinase Kd 6.68 CHEMBL
Ephrin type-A receptor 3 Kinase Kd 10.03 CHEMBL
Mitogen-activated protein kinase 14 Kinase Kd 7.57 CHEMBL
Tyrosine-protein kinase FRK Kinase INHIBITOR Kd 9.51 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 5 Kinase Kd 7.35 CHEMBL
Mitogen-activated protein kinase kinase kinase 4 Kinase Kd 6.51 CHEMBL
Cyclin-G-associated kinase Kinase Kd 8.59 CHEMBL
Receptor-interacting serine/threonine-protein kinase 2 Kinase Kd 7.51 CHEMBL
Ephrin type-B receptor 1 Kinase Kd 9.35 CHEMBL
Serine/threonine-protein kinase 4 Kinase Kd 5.42 CHEMBL
Activated CDC42 kinase 1 Kinase Kd 8.25 CHEMBL
STE20-like serine/threonine-protein kinase Kinase Kd 6.14 CHEMBL
Epithelial discoidin domain-containing receptor 1 Kinase Kd 9.16 CHEMBL
Ephrin type-B receptor 4 Kinase Kd 9.47 CHEMBL
Activin receptor type-1B Kinase Kd 6.48 CHEMBL
Serine/threonine-protein kinase receptor R3 Kinase Kd 6.34 CHEMBL
Activin receptor type-1 Kinase Kd 6.21 CHEMBL
TGF-beta receptor type-2 Kinase Kd 5.54 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 1 Kinase Kd 6 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 2 Kinase Kd 5.85 CHEMBL
Tyrosine-protein kinase ITK/TSK Kinase IC50 6.64 CHEMBL
Protein-tyrosine kinase 6 Kinase Kd 8.11 CHEMBL
MAP kinase-activated protein kinase 2 Kinase Kd 6.27 CHEMBL
Tyrosine-protein kinase BTK Kinase Kd 8.85 CHEMBL
Tyrosine-protein kinase Tec Kinase Kd 7.89 CHEMBL
Ephrin type-B receptor 2 Kinase Kd 9.41 CHEMBL
Non-receptor tyrosine-protein kinase TNK1 Kinase Kd 6.17 CHEMBL
Non-receptor tyrosine-protein kinase TYK2 Kinase Kd 6.96 CHEMBL
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Kinase IC50 4.42 CHEMBL
Wee1-like protein kinase Kinase Kd 5.15 CHEMBL
Serine/threonine-protein kinase 25 Kinase Kd 5.47 CHEMBL
Mitogen-activated protein kinase kinase kinase MLT Kinase Kd 7.35 CHEMBL
Tyrosine-protein kinase TXK Kinase Kd 8.68 CHEMBL
LIM domain kinase 2 Kinase Kd 7.07 CHEMBL
Serine/threonine-protein kinase 26 Kinase Kd 5.72 CHEMBL
Serine/threonine-protein kinase NLK Kinase Kd 6.59 CHEMBL
Eukaryotic translation initiation factor 2-alpha kinase 4 Kinase Kd 5.80 CHEMBL
Serine/threonine-protein kinase SIK2 Kinase Kd 8.19 CHEMBL
Activin receptor type-2A Kinase Kd 6.68 CHEMBL
Activin receptor type-2B Kinase Kd 6.24 CHEMBL
Serine/threonine-protein kinase TNNI3K Kinase Kd 7.96 CHEMBL
Discoidin domain-containing receptor 2 Kinase Kd 8.52 CHEMBL
Myotonin-protein kinase Kinase Kd 5.89 CHEMBL
Chaperone activity of bc1 complex-like, mitochondrial Kinase Kd 6.72 CHEMBL
Serine/threonine-protein kinase MRCK gamma Kinase Kd 5.92 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 1 Kinase Kd 6.01 CHEMBL
Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase Kinase Kd 6.89 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 3 Kinase Kd 6.19 CHEMBL
Aurora kinase B Kinase IC50 5.19 CHEMBL
Tyrosine-protein kinase Blk Kinase INHIBITOR Kd 9.68 CHEMBL
Bone morphogenetic protein receptor type-1A Kinase Kd 5.15 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 4 Kinase Kd 5.51 CHEMBL
Serine/threonine-protein kinase MRCK alpha Kinase Kd 5.70 CHEMBL
Serine/threonine-protein kinase MRCK beta Kinase Kd 5.68 CHEMBL
Serine/threonine-protein kinase PAK 4 Kinase Kd 6.13 CHEMBL
Serine/threonine-protein kinase SIK1 Kinase Kd 8.41 CHEMBL
Tyrosine-protein kinase Srms Kinase INHIBITOR Kd 7.89 CHEMBL
Dual specificity testis-specific protein kinase 1 Kinase Kd 7.48 CHEMBL
TGF-beta receptor type-1 Kinase Kd 6.64 CHEMBL
Ephrin type-A receptor 1 Kinase Kd 8.39 CHEMBL
Ephrin type-B receptor 3 Kinase Kd 8.16 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 2 Kinase Kd 5.89 CHEMBL
Misshapen-like kinase 1 Kinase Kd 6.37 CHEMBL
Ephrin type-B receptor 6 Kinase Kd 10.41 CHEMBL
Mitogen-activated protein kinase kinase kinase 13 Kinase Kd 5.28 CHEMBL
Mitogen-activated protein kinase kinase kinase 2 Kinase Kd 6.85 CHEMBL
Mitogen-activated protein kinase kinase kinase 3 Kinase Kd 6.55 CHEMBL
Mitogen-activated protein kinase kinase kinase 7 Kinase Kd 5.43 CHEMBL
Serine/threonine-protein kinase TAO3 Kinase Kd 5.64 CHEMBL
Serine/threonine-protein kinase ULK3 Kinase Kd 5.34 CHEMBL
Mitogen-activated protein kinase kinase kinase 19 Kinase Kd 7.10 CHEMBL
Serine/threonine-protein kinase 35 Kinase Kd 6.11 CHEMBL
Receptor tyrosine-protein kinase erbB-3 Kinase Kd 7.74 CHEMBL
Mitogen-activated protein kinase kinase kinase 1 Kinase Kd 5.90 CHEMBL
Serine/threonine-protein kinase SIK3 Kinase Kd 7.55 CHEMBL
Wee1-like protein kinase 2 Kinase Kd 6.70 CHEMBL
Bone morphogenetic protein receptor type-1B Kinase Kd 7.28 CHEMBL
Serine/threonine-protein kinase SBK1 Kinase Kd 5.92 CHEMBL
Serine/threonine-protein kinase VRK2 Kinase Kd 5.49 CHEMBL
Serine/threonine-protein kinase TAO2 Kinase Kd 5.27 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5 Kinase Kd 8.48 CHEMBL
Serine/threonine-protein kinase Nek11 Kinase Kd 6.33 CHEMBL
MAP kinase p38 Kinase IC50 7 CHEMBL
Dual specificity mitogen-activated protein kinase kinase; MEK1/2 Kinase IC50 5.77 CHEMBL
Bcr/Abl fusion protein Kinase IC50 9.10 CHEMBL
Tyrosine-protein kinase JAK3 Kinase Kd 6.19 CHEMBL
Myelin transcription factor 1 Transcription factor IC50 7.20 CHEMBL
Epidermal growth factor receptor Kinase Kd 7.10 CHEMBL
Serine/threonine-protein kinase mTOR Kinase IC50 4.46 CHEMBL
Breakpoint cluster region protein Kinase Kd 8.30 CHEMBL
RAF proto-oncogene serine/threonine-protein kinase Kinase Kd 6.24 CHEMBL
Serine/threonine-protein kinase B-raf Kinase Kd 6.30 CHEMBL
Receptor-type tyrosine-protein kinase FLT3 Kinase Kd 5.49 CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret Kinase Kd 6.41 CHEMBL
Proto-oncogene tyrosine-protein kinase LCK Kinase Ki 10.19 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase Kd 7.96 CHEMBL
Tubulin alpha-1A chain Structural Kd 7.26 CHEMBL
Tyrosine-protein kinase Blk Kinase IC50 8.10 CHEMBL
Quinolone resistance protein NorA Transporter IC50 4.94 CHEMBL
Calcium-dependent protein kinase 1 Kinase Kd 6.19 CHEMBL

External reference:

IDSource
4025488 VUID
N0000179780 NUI
D03658 KEGG_DRUG
475342 RXNORM
4025488 VANDF
C1455147 UMLSCUI
CHEBI:70839 CHEBI
1N1 PDB_CHEM_ID
CHEMBL1421 ChEMBL_ID
D000069439 MESH_DESCRIPTOR_UI
DB01254 DRUGBANK_ID
5678 IUPHAR_LIGAND_ID
RBZ1571X5H UNII
3062316 PUBCHEM_CID
21648 MMSL
83173 MMSL
d05831 MMSL
011616 NDDF
422756008 SNOMEDCT_US
423658008 SNOMEDCT_US
863127-77-9 SECONDARY_CAS_RN

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 0003-0524 TABLET 70 mg ORAL NDA 27 sections
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 0003-0527 TABLET 20 mg ORAL NDA 27 sections
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 0003-0528 TABLET 50 mg ORAL NDA 27 sections
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 0003-0852 TABLET 100 mg ORAL NDA 27 sections
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 0003-0855 TABLET 80 mg ORAL NDA 27 sections
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 0003-0857 TABLET 140 mg ORAL NDA 27 sections
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 54868-5759 TABLET 70 mg ORAL NDA 28 sections